{
    "clinical_study": {
        "@rank": "122743", 
        "arm_group": [
            {
                "arm_group_label": "1.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight"
            }, 
            {
                "arm_group_label": "2.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight"
            }, 
            {
                "arm_group_label": "3.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight"
            }, 
            {
                "arm_group_label": "4.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight"
            }, 
            {
                "arm_group_label": "5.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight"
            }, 
            {
                "arm_group_label": "6.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight"
            }, 
            {
                "arm_group_label": "7.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight"
            }, 
            {
                "arm_group_label": "8.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight"
            }, 
            {
                "arm_group_label": "9.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight"
            }, 
            {
                "arm_group_label": "10.Remimazolam Tosylate", 
                "arm_group_type": "Experimental", 
                "description": "Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight"
            }, 
            {
                "arm_group_label": "11.Midazolam", 
                "arm_group_type": "Active Comparator", 
                "description": "Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate and compare the Pharmacokinetics/Pharmacodynamics\n      and safety of Remimazolam Tosylate with midazolam in  healthy volunteers"
        }, 
        "brief_title": "A Phase \u2160a Study of Remimazolam Tosylate in Healthy Volunteers", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or females\n\n          -  Weight range 50 to 100 kg inclusive\n\n          -  Body mass index (BMI) 18 to 26 kg/m2\n\n        Exclusion Criteria:\n\n          -  Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a\n             medical condition such that these agents are contraindicated\n\n          -  With evidence of uncontrolled renal, hepatic, central nervous system, respiratory,\n             cardiovascular, or metabolic dysfunction, in the opinion of the investigator or\n             medical monitor\n\n          -  Has known or suspected history of alcoholism or drug abuse or misuse within 6 months\n             of Screening or evidence of tolerance or physical dependence before dosing with study\n             drug\n\n          -  With a history of laboratory results that show the presence of hepatitis B surface\n             antigen (HBs Ag), hepatitis C antibody (HCV Ab), or human immunodeficiency virus\n             (HIV)\n\n          -  Pregnant,lactating\n\n          -  Mallampati score \u22653"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970072", 
            "org_study_id": "RMZL-PIa"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1.Remimazolam Tosylate", 
                    "2.Remimazolam Tosylate", 
                    "3.Remimazolam Tosylate", 
                    "4.Remimazolam Tosylate", 
                    "5.Remimazolam Tosylate", 
                    "6.Remimazolam Tosylate", 
                    "7.Remimazolam Tosylate", 
                    "8.Remimazolam Tosylate", 
                    "9.Remimazolam Tosylate", 
                    "10.Remimazolam Tosylate"
                ], 
                "intervention_name": "Remimazolam Tosylate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "11.Midazolam", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Remimazolam Tosylate", 
            "Phase \u2160 study", 
            "Health"
        ], 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "contact": {
                "email": "pei.hu.pumc@gmail.com", 
                "last_name": "Bei Hu, Professor", 
                "phone": "86-010-69158366"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100032"
                }, 
                "name": "Peking Union Medical College Hospital"
            }, 
            "investigator": {
                "last_name": "Bei Hu, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "11", 
        "official_title": "A Placebo- and Midazolam-Controlled, Phase Ia, Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam Tosylate", 
        "overall_contact": {
            "email": "pei.hu.pumc@gmail.com", 
            "last_name": "Bei Hu, Professor", 
            "phone": "86-010-69158366"
        }, 
        "overall_official": {
            "affiliation": "Peiking Union Medical College Hospital", 
            "last_name": "Bei Hu, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "To study the Pharmacokinetics of Remimazolam Tosylate by assessment of drug concentration through blood sample analysis", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 8 hours post-dosee"
            }, 
            {
                "measure": "Bispectral index (BIS) and Modified Observer's Assessment of Alertness/Sedation(MOAA/S) score assessments", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 2 hours post-dose"
            }, 
            {
                "measure": "Adverse event\uff1bVital sign\uff1bPhysical examination\uff1bLaboratory examination\uff1bECG\uff1bThe nervous system function test", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose to 24 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970072"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}